Drug Trial Radar · NCT06449222
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Actual
Start
Aug 26, 2024
Primary completion
Aug 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Conditions
- Locally Advanced Breast Cancer
- Triple Negative Breast Cancer
- Metastatic Triple Negative Breast Cancers
Interventions
BNT327 Dose Level 1 (DL1)Drug
Intravenous (IV) infusion
BNT327 Dose Level 1 (DL2)Drug
IV infusion
Nab-placlitaxelDrug
IV infusion
CarboplatinDrug
IV infusion
GemcitabineDrug
IV infusion
PaclitaxelDrug
IV infusion
EribulinDrug
IV infusion
BNT327 Optimized DoseDrug
IV infusion
BNT327 Equivalent Q3W DoseDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment emergent serious adverse events (SAEs)Time frame: up to 100 days after the last dose of treatment
- Occurrence of dose interruption, dose reduction, and discontinuation of study treatment due to adverse events (AEs)Time frame: up to 100 days after the last dose of treatment
- Objective Response Rate (ORR)Time frame: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
- Best percentage change from baseline in the tumor sizeTime frame: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
- Proportion of participants who have achieved early tumor shrinkageTime frame: up to 4 months after first dose of treatment
Locations
31 sites in 4 countries. Site status is shown where the registry gives one.
Beverly Hills Cancer Center
Beverly Hills, California
Valkyrie Clinical Trials
Los Angeles, California
Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center
Palo Alto, California
Saint John's Health Center - John Wayne Cancer Institute (JWCI)
Santa Monica, California
Rocky Mountain Cancer Centers (RMCC)
Denver, Colorado
Yale University - Yale Cancer Center
New Haven, Connecticut
Carle Foundation Hospital d/b/a Carle Cancer Center
Urbana, Illinois
HealthPartners Regions Specialty Clinics
Saint Louis Park, Minnesota
Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey)
New Brunswick, New Jersey
Stony Brook University Hospital
Stony Brook, New York
The West Clinic, P.C. d/b/a West Cancer Center
Germantown, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Bon Secours St. Francis Medical Center
Midlothian, Virginia
Peninsula Oncology Centre
Frankston, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Baskent Universitesi Tip Fakultesi Adana Hastanesi
Adana, Turkey (Türkiye)
Medical Park Seyhan Hospital
Adana, Turkey (Türkiye)
Sakarya University - Faculty of Medicine
Adapazarı, Turkey (Türkiye)
Hacettepe Universitesi Kanser Enstitusu
Ankara, Turkey (Türkiye)
Sbu Dr.A.Y. Ankara Onkoloji SUAM
Ankara, Turkey (Türkiye)
Memorial Ankara Hospital
Ankara, Turkey (Türkiye)
Koc Universitesi Hastanesi (Koc University Hospital)
Istanbul, Turkey (Türkiye)
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
Istanbul, Turkey (Türkiye)
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, Turkey (Türkiye)
Yeditepe University Hospital
Istanbul, Turkey (Türkiye)
Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital
Cottingham, United Kingdom
Edinburgh Cancer Centre-Western General Hospital
Edinburgh, United Kingdom
St James's University Hospital - Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
St Bartholomew's Hospital - Barts Health NHS Trust
London, United Kingdom
Sarah Cannon Research Institute
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.